Michelle Curran, PhD, is currently the Lead Clinical Scientist at Roche, supporting Global Phase III HER2-Immunotherapy combination trials in Early Breast Cancer. With expertise in PhI/II clinical development, Michelle previously held roles at AstraZeneca as a Clinical Scientist and Postdoctoral Research Fellow, where they developed translational humanised mouse models and assessed novel therapies. Their academic background includes a PhD in Immunology from the University of Birmingham, as well as a Master's from Trinity College Dublin and a Bachelor's from Dublin City University. Michelle is passionate about innovative science that enhances therapeutic delivery to patients.
This person is not in the org chart
This person is not in any teams
This person is not in any offices